graded according to the World Health Organi 2 :ation (WHO) recommendations (see 
Appendix 3). 
7.0 SAFETY AND EFFICACY 
No more than two weeks prior to entry into the study, and several times during the 
study according to the Schedule of Events chart (Appendix 1), all patients will have the 
following studies performed to assess their disease status: 
7.1 Physical excim and medical history including height, weight, performance status 
and tumor measurements (tumor staging and by physical exam (when 
accessible). 
7.2 Chest X-ray. 
7.3 EKG. 
7.4 CBC, platelet count, differential, PT, PTT. 
7.5 Blood chemistries: creatinine, BUN, bilirubin, alkaline phosphatase, LDH, 
SCOT, SGPT, phosphorus, uric add, caldum, total protein, albumin, glucose. 
7.6 Merieux Multlitest skin tests 
7.7 Lymphocyte Proliferative Response to PHA. 
7.8 Pregnaincy test for women. 
7.9 HIV antibody test. 
7.10 Hepatitis screen- 
7.11 Tumor biopsies. 
7.12 CT/MRI/Ultrasound (if relevant) for baseline and to evaluate status of disease. 
7.13 Spectial Tests: Blood will be drawn for serum to be analyzed by PCR for the 
presence of the plasmid and antibody to FILA-B7. PBLs will be isolated and 
analyzed for their ability to lyse HLA-B7 modified autologous EBV-transformed 
lines. 
7.14 Blood draws during this study will be limited to a maximum of 50 ml each. 
Recombinant DNA Research, Volume 19 
[247] 
